4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts. With a volatile equity market and a potential recession looming due to the impact of tariffs, dividend stocks can help strengthen any portfolio.With that as a backdrop, let's consider four excellent income stocks that investors can buy amid the current sell-off: AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), and Zoetis (NYSE: ZTS).AbbVie is a leading drugmaker best known for its work in immunology. The company has encountered some issues in recent years, including a major patent cliff and a clinical setback for a product many thought looked promising. However, AbbVie's financial results remain solid. Thanks to medicines such as Skyrizi and Rinvoq, which treat a range of autoimmune conditions, AbbVie's revenue is moving in the right direction.Continue reading
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts. With a volatile equity market and a potential recession looming due to the impact of tariffs, dividend stocks can help strengthen any portfolio.
With that as a backdrop, let's consider four excellent income stocks that investors can buy amid the current sell-off: AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), and Zoetis (NYSE: ZTS).
AbbVie is a leading drugmaker best known for its work in immunology. The company has encountered some issues in recent years, including a major patent cliff and a clinical setback for a product many thought looked promising. However, AbbVie's financial results remain solid. Thanks to medicines such as Skyrizi and Rinvoq, which treat a range of autoimmune conditions, AbbVie's revenue is moving in the right direction.
